FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Zalupski

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Jeffrey M Vainshtein; Mark M Zalupski; Ross Abrams; Isaac R Francis; Gazala Khan; Theodore S Lawrence; William Leslie; Matthew Schipper; Edgar Ben-Josef
Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Huan T Ha; David R Lucas; Scott M Schuetze; Dafydd Thomas; Mark M Zalupski; Laurence H Baker; Kent Andrew Griffith; Rashmi Chugh
Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.
Todd M Bauer; Bassel F El-Rayes; Nazik Hammad; Xiaobai Li; Philip A Philip; Anthony F Shields; Mark M Zalupski; Tanios Bekaii-Saab
Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Zalupski (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jeffrey M Vainshtein; Mark M Zalupski; Ross Abrams; Isaac R Francis; Gazala Khan; Theodore S Lawrence; William Leslie; Matthew Schipper; Edgar Ben-Josef
Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
International journal of radiation oncology, biology, physics 2013;86(1):96-101.
2013: Huan T Ha; David R Lucas; Scott M Schuetze; Dafydd Thomas; Mark M Zalupski; Laurence H Baker; Kent Andrew Griffith; Rashmi Chugh
Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.
American journal of clinical oncology 2013;36(1):77-82.
2013: Todd M Bauer; Bassel F El-Rayes; Nazik Hammad; Xiaobai Li; Philip A Philip; Anthony F Shields; Mark M Zalupski; Tanios Bekaii-Saab
Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Cancer 2013;119(2):285-92.
2013: Jordan Berlin; Gordon L Bray; Irfan Firdaus; Ira Gore; Richard A Graham; Lowell L Hart; Robert C Hermann; Howard M Mackey; Mary F Mulcahy; Robert L Yauch; Mark M Zalupski; Johanna C Bendell; Jennifer A Low
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(1):258-67.
2013: JOSEPH HERMAN; Theodore S Lawrence; Amol K Narang; Leah Olsen; Jennifer B Reese; Mark M Zalupski; June L Chan; Jonathan Efron; Susan L Gearhart; Kent A Griffith; Nilofer S Azad; Edgar Ben-Josef
The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer.
International journal of radiation oncology, biology, physics 2013;85(1):e15-9.
2012: Edgar Ben-Josef; Isaac R Francis; Scott W Hadley; Gazala Khan; Theodore S Lawrence; William Leslie; Daniel Normolle; Matthew Schipper; Diane M Simeone; Christopher J Sonnenday; Randall TenHaken; Ross Abrams; Mark M Zalupski
A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
International journal of radiation oncology, biology, physics 2012;84(5):1166-71.
2012: L K Martin; Mark M Zalupski; M Bloomston; E C Ellison; B Kleiber; X Li; Tanios Bekaii-Saab
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(11):2812-20.
2012: Caio M Rocha Lima; Ovidiu C Trifan; Mark M Zalupski; Miklos L Auber; Jeffrey K Giguere; Remigiusz Kaleta; George P Kim; Edward H Lin; John Marshall; M Brent McHenry; Chris Papageorgio; Philip A Philip
A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer.
Gastrointestinal cancer research : GCR 2012;5(5):155-60.
2012: Klaudia U Hunter; Theodore S Lawrence; James D Murphy; Mark M Zalupski; Sameer Desai; Felix Y Feng; Isaac R Francis; Kent Andrew Griffith; Edgar Ben-Josef
Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
International journal of radiation oncology, biology, physics 2012;83(3):921-6.
2012: Scott M Schuetze; Dafydd Thomas; Mark M Zalupski; Lili Zhao; Rashmi Chugh; David R Lucas; Gino Metko; Laurence H Baker
Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.
European journal of cancer (Oxford, England : 1990) 2012;48(9):1347-53.
2012: Andrew D Boyd; Doris Brown; Janet Hampton; Chris Henrickson; Diane M Simeone; Jeremy M G Taylor; Mark M Zalupski; Bin Zhu; Farideh Almani; Roseanne Armitage; Edgar Ben-Josef; Michelle B Riba
Screening for depression, sleep-related disturbances, and anxiety in patients with adenocarcinoma of the pancreas: a preliminary study.
TheScientificWorldJournal 2012;2012():650707.
2012: Joshua Peck; Miguel Villalona Calero; Lai Wei; Mark M Zalupski; Bert O Neil; Tanios Bekaii-Saab
HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.
Oncology 2012;82(3):175-9.
2011: Edward J Kim; Mark M Zalupski
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Journal of surgical oncology 2011;104(8):901-6.
2011: Marisa E Hill; Xiaobai Li; Sharon Kim; Angela Campbell; Kristy Culler; Mark Bloomston; Mark M Zalupski; Gwen Hejna; Tanios Bekaii-Saab
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Cancer chemotherapy and pharmacology 2011;67(3):511-7.
2010: Craig M Womeldorph; Mark M Zalupski; Stewart M Knoepp; Mohammad Soltani; B Joseph Elmunzer
Retroperitoneal germ cell tumor diagnosed by endoscopic ultrasound-guided fine needle aspiration.
World journal of gastrointestinal oncology 2010;2(12):443-5.
2010: Basil F El-Rayes; Pallavi Jasti; Richard K Severson; Khaldoun Almhanna; Philip A Philip; Anthony F Shields; Mark M Zalupski; Lance K Heilbrun
Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials.
Pancreas 2010;39(7):967-71.
2010: Basil F El-Rayes; Mark M Zalupski; T Bekai-Saab; Lance K Heilbrun; N Hammad; Bhaumik B Patel; Susan G Urba; Anthony F Shields; Ulka Nitin Vaishampayan; S Dawson; Khaldoun Almhanna; D Smith; Philip A Philip
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(10):1999-2004.
2010: Steven J Cohen; Mark M Zalupski; Manuel R Modiano; Paul Conkling; Yehuda Z Patt; Peg Davis; Robert T Dorr; Michelle L Boytim; Evan M Hersh
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
Cancer chemotherapy and pharmacology 2010;66(2):287-94.
2010: Nazik Hammad; Lance K Heilbrun; Philip A Philip; Anthony F Shields; Mark M Zalupski; Raghu Venkatramanamoorthy; Basil F El-Rayes
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
Asia-Pacific journal of clinical oncology 2010;6(2):98-105.
2010: Minsig Choi; Lance K Heilbrun; Raghu Venkatramanamoorthy; Jawana M Lawhorn-Crews; Mark M Zalupski; Anthony F Shields
Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
American journal of clinical oncology 2010;33(3):257-61.
2009: Sameer Desai; Edgar Ben-Josef; Kent Andrew Griffith; Diane M Simeone; Joel K Greenson; Isaac R Francis; Janet Hampton; Lisa M Colletti; Alfred E Chang; Theodore S Lawrence; Mark M Zalupski
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
International journal of radiation oncology, biology, physics 2009;75(5):1450-5.
2009: Joseph N Contessa; Kent Andrew Griffith; Elizabeth Wolff; William D Ensminger; Mark M Zalupski; Theodore S Lawrence; Edgar Ben-Josef
Radiotherapy for pancreatic neuroendocrine tumors.
International journal of radiation oncology, biology, physics 2009;75(4):1196-200.
2009: Gazala N Khan; Masood Siddiqui; Edgar Ben-Josef; Mark M Zalupski
An unusual case of small cell carcinoma of the anal canal.
American journal of clinical oncology 2009;32(5):543-4.
2009: Tanios Bekaii-Saab; Joseph Markowitz; Nichole Prescott; Wolfgang Sadee; Nyla A Heerema; Lai Wei; Zunyan Dai; Audrey Papp; Angela Campbell; Kristy Culler; Catherine Balint; Bert O Neil; Ruey-Min Lee; Mark M Zalupski; Janet Dancey; Helen Chen; Michael R Grever; Charis Eng; Miguel A Villalona-Calero
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(18):5895-901.
2009: Elaina Gartner; Kent Andrew Griffith; Quintin Pan; George J Brewer; Gwen F Henja; Sofia D Merajver; Mark M Zalupski
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
Investigational new drugs 2009;27(2):159-65.
2008: William Small; Jordan Berlin; Gary M Freedman; Theodore S Lawrence; Mark S Talamonti; Mary F Mulcahy; A Bapsi Chakravarthy; Andre Konski; Mark M Zalupski; Philip A Philip; Timothy J Kinsella; Nipun B Merchant; John P Hoffman; Al B Benson; Steven Nicol; Rong M Xu; John F Gill; Cornelius J McGinn
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(6):942-7.
2008: Basil F El-Rayes; Mark M Zalupski; Stephanie G Manza; Barbara Rusin; Ann Marie Ferris; Ulka Nitin Vaishampayan; Lance K Heilbrun; Raghu Venkatramanamoorthy; Anthony F Shields; Philip A Philip
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Cancer chemotherapy and pharmacology 2008;61(2):283-9.
2007: Edgar Ben-Josef; Theodore S Lawrence; Mark M Zalupski
Radiotherapy for locally advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4861.
2007: Sameer P Desai; Edgar Ben-Josef; Daniel Normolle; Isaac R Francis; Joel K Greenson; Diane M Simeone; Alfred E Chang; Lisa M Colletti; Theodore S Lawrence; Mark M Zalupski
Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4587-92.
2007: Bryan J Schneider; Basil F El-Rayes; Jeffrey H Muler; Philip A Philip; Gregory P Kalemkerian; Kent Andrew Griffith; Mark M Zalupski
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Cancer 2007;110(4):770-5.
2007: Sameer P Desai; Basil F El-Rayes; Edgar Ben-Josef; Joel K Greenson; James A Knol; Emina H Huang; Kent Andrew Griffith; Philip A Philip; Cornelius J McGinn; Mark M Zalupski
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
American journal of clinical oncology 2007;30(4):340-5.
2007: tudor ciuleanu; M Diculescu; Nicolas Hoepffner; J Trojan; V Sailer; Mark M Zalupski; T Herrmann; A Roth; Jon B Chick; K Brock; D Albert; Philip A Philip
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
Investigational new drugs 2007;25(4):385-90.
2007: James Murphy; Saroja Adusumilli; Kent Andrew Griffith; Michael E Ray; Mark M Zalupski; Theodore S Lawrence; Edgar Ben-Josef
Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.
International journal of radiation oncology, biology, physics 2007;68(3):801-8.
2007: Rashmi Chugh; Thomas Wagner; Kent Andrew Griffith; Jeremy Taylor; Dafydd Thomas; Francis P Worden; Kirsten M Leu; Mark M Zalupski; Laurence H Baker
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
Cancer 2007;109(11):2315-22.
2007: Basil F El-Rayes; Mark M Zalupski; Anthony F Shields; Stephanie G Manza; Patricia M LoRusso; Philip A Philip
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
American journal of clinical oncology 2007;30(2):101-5.
2006: Merav A Ben-David; Kent Andrew Griffith; Eyad Abu-Isa; Theodore S Lawrence; James A Knol; Mark M Zalupski; Edgar Ben-Josef
External-beam radiotherapy for localized extrahepatic cholangiocarcinoma.
International journal of radiation oncology, biology, physics 2006;66(3):772-9.
2006: Tanios S Bekaii-Saab; Amir Mortazavi; Lee G Hicks; Mark M Zalupski; Robert J Pelley; Kenneth K Chan; Eric H Kraut
A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC).
Investigational new drugs 2006;24(4):343-6.
2006: Gary Von Burton; Cathy Rankin; Mark M Zalupski; Glen M Mills; Ernest C Borden; Antman Karen
Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
American journal of clinical oncology 2006;29(1):59-61.
2006: Mark S Talamonti; William Small; Mary F Mulcahy; Jeffrey D Wayne; Vikram Attaluri; Lisa M Colletti; Mark M Zalupski; John P Hoffman; Gary M Freedman; Timothy J Kinsella; Philip A Philip; Cornelius J McGinn
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.
Annals of surgical oncology 2006;13(2):150-8.
2005: Basil F El-Rayes; Mark M Zalupski; Anthony F Shields; Ann Marie Ferris; Ulka Nitin Vaishampayan; Lance K Heilbrun; Raghu Venkatramanamoorthy; Volkan Adsay; Philip A Philip
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Investigational new drugs 2005;23(6):583-90.
2005: Bryan J Schneider; Edgar Ben-Josef; Cornelius J McGinn; Alfred E Chang; Lisa M Colletti; Daniel Normolle; Gwen Hejna; Theodore S Lawrence; Mark M Zalupski
Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer.
International journal of radiation oncology, biology, physics 2005;63(5):1325-30.
2005: Cynthia G Leichman; Jacqueline K Benedetti; Mark M Zalupski; Howard Hochster; Anthony F Shields; Heinz-Josef Lenz; James L Wade Iii; James D Bearden Iii; John S Macdonald
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
Clinical colorectal cancer 2005;5(2):119-23.
2005: Rashmi Chugh; Rodney Dunn; Mark M Zalupski; J Sybil Biermann; vernon sondak; Joseph R Mace; Kirsten M Leu; William F Chandler; Laurence H Baker
Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3597-604.
2005: Basil F El-Rayes; Anthony F Shields; Mark M Zalupski; Lance K Heilbrun; Vikash Jain; Damita Terry; Ann Marie Ferris; Philip A Philip
A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary.
American journal of clinical oncology 2005;28(2):152-6.
2005: Francis P Worden; Jeremy Taylor; J Sybil Biermann; vernon sondak; Kirsten M Leu; Rashmi Chugh; Cornelius J McGinn; Mark M Zalupski; Laurence H Baker
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):105-12.
2005: Basil F El-Rayes; Dina Ibrahim; Anthony F Shields; Patricia M LoRusso; Mark M Zalupski; Philip A Philip
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
Investigational new drugs 2005;23(1):57-62.
2004: Aaron M. Allen; Mark M Zalupski; John M Robertson; Frederic E Eckhauser; Diane Simone; Diane Brown; Gwen Hejna; Daniel Normolle; Theodore S Lawrence; Cornelius J McGinn
Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
International journal of radiation oncology, biology, physics 2004;59(5):1461-7.
2004: Basil F El-Rayes; Anthony F Shields; Mark M Zalupski; Lance K Heilbrun; Vikash Jain; D Terry; Ann Marie Ferris; Philip A Philip
A phase II study of carboplatin and paclitaxel in esophageal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(6):960-5.
2004: Kirsten M Leu; Leo J Ostruszka; Donna S Shewach; Mark M Zalupski; vernon sondak; J Sybil Biermann; Julia Shin-Jung Lee; Carol Couwlier; Krisinda Palazzolo; Laurence H Baker
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1706-12.
2004: Mark M Zalupski; Cathryn Rankin; James R Ryan; David R Lucas; Jeffrey H Muler; Keith S Lanier; G Thomas Budd; J Sybil Biermann; Frederick J Meyers; Karen Antman
Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
Cancer 2004;100(4):818-25.
2004: Anthony F Shields; Mark M Zalupski; John L Marshall; Neal J Meropol
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
Cancer 2004;100(3):531-7.
2004: Jeffrey H Muler; Cornelius J McGinn; Daniel Normolle; Theodore S Lawrence; Diane Brown; Gwen Hejna; Mark M Zalupski
Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(2):238-43.
2003: Sana Al-Sukhun; Mark M Zalupski; Edgar Ben-Josef; Vainutis K Vaitkevicius; Philip A Philip; Renate Soulen; Donald Willard Weaver; Volkan Adsay; Lance K Heilbrun; Kenneth Levin; Jeffrey D Forman; Anthony F Shields
Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
American journal of clinical oncology 2003;26(6):543-9.
2003: John B Ammori; Lisa M Colletti; Mark M Zalupski; Frederic E Eckhauser; Joel K Greenson; Justin B Dimick; Theodore S Lawrence; Cornelius J McGinn
Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2003;7(6):766-72.
2003: Basil F El-Rayes; Mark M Zalupski; Anthony F Shields; Ulka Nitin Vaishampayan; Lance K Heilbrun; V Jain; Volkan Adsay; J Day; Philip A Philip
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(15):2920-5.
2003: Shirish M Gadgeel; Ramesh R Boinpally; Lance K Heilbrun; Antoinette J Wozniak; Vikash Jain; Bruce G Redman; Mark M Zalupski; Richard A Wiegand; Ralph E Parchment; Patricia M LoRusso
A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.
Investigational new drugs 2003;21(1):63-74.
2003: Shirish M Gadgeel; Anthony F Shields; Lance K Heilbrun; Samir Labadidi; Mark M Zalupski; Ruth Chaplen; Philip A Philip
Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer.
American journal of clinical oncology 2003;26(1):37-41.
2003: Cornelius J McGinn; Mark M Zalupski
Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials.
International journal of radiation oncology, biology, physics 2003;56(4 Suppl):10-5.
2002: Jeffrey H Muler; Laurence H Baker; Mark M Zalupski
Gastrointestinal stromal tumors: chemotherapy and imatinib.
Current oncology reports 2002;4(6):499-503.
2002: Cornelius J McGinn; Theodore S Lawrence; Mark M Zalupski
On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer.
Cancer 2002;95(4 Suppl):933-40.
2002: Zvi Symon; Mary Davis; Cornelius J McGinn; Mark M Zalupski; Theodore S Lawrence
Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic.
International journal of radiation oncology, biology, physics 2002;53(1):140-5.
2002: Patricia M LoRusso; Sucharu Prakash; Antoinette J Wozniak; Lawrence E Flaherty; Mark M Zalupski; Anthony F Shields; Howard Sands; Ralph E Parchment; Bhaskara R Jasti
Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).
Investigational new drugs 2002;20(1):63-71.
2001: Cornelius J McGinn; Mark M Zalupski; Imad Shureiqi; John M Robertson; Frederic E Eckhauser; David C Smith; Diane Brown; Gwen Hejna; Myla S Strawderman; Daniel Normolle; Theodore S Lawrence
Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(22):4202-8.
2001: Philip A Philip; Mark M Zalupski; Vainutis K Vaitkevicius; Patricia Arlauskas; Ruth Chaplen; Lance K Heilbrun; Volkan Adsay; Donald Willard Weaver; Anthony F Shields
Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
Cancer 2001;92(3):569-77.
2001: Cornelius J McGinn; Mark M Zalupski
Combined-modality therapy in pancreatic cancer: current status and future directions.
Cancer journal (Sudbury, Mass.) 2001;7(4):338-48.
2001: Anthony F Shields; L M Lange; Mark M Zalupski
Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer.
American journal of clinical oncology 2001;24(1):96-8.
2001: S Prakash; Brenda J Foster; M Meyer; Antoinette J Wozniak; Lance K Heilbrun; Lawrence E Flaherty; Mark M Zalupski; L Radulovic; Manuel Valdivieso; Patricia M LoRusso
Chronic oral administration of CI-994: a phase 1 study.
Investigational new drugs 2001;19(1):1-11.
2001: Jeffrey A Zonder; Anthony F Shields; Mark M Zalupski; Ruth Chaplen; Lance K Heilbrun; Patricia Arlauskas; Philip A Philip
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(1):38-42.
2000: S Ahmed; Vainutis K Vaitkevicius; Mark M Zalupski; Wei Du; Patricia Arlauskas; C Gordon; C Kellogg; Anthony F Shields
Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study.
American journal of clinical oncology 2000;23(4):420-4.
1999: R E Jimenez; Mark M Zalupski; J J Frank; Wei Du; James R Ryan; David R Lucas
Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy.
Cancer 1999;86(6):976-81.
1999: David R Lucas; C D Fletcher; N Volkan Adsay; Mark M Zalupski
High-grade extraskeletal myxoid chondrosarcoma: a high-grade epithelioid malignancy.
Histopathology 1999;35(3):201-8.
1999: Cynthia G Leichman; J R Jacobson; M Modiano; J R Daniels; Mark M Zalupski; James Doroshow; W S Fletcher; John S Macdonald
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial.
Cancer 1999;86(5):775-81.
1999: Philip A Philip; Dina Ibrahim; Mark M Zalupski; Patricia Arlauskas; Anthony F Shields
Gemcitabine and UFT plus oral calcium folinate: phase I study.
Oncology (Williston Park, N.Y.) 1999;13(7 Suppl 3):116-9.
1999: Anthony F Shields; Philip A Philip; Patricia M LoRusso; Ann Marie Ferris; Mark M Zalupski
Phase II study of CI-958 in colorectal cancer.
Cancer chemotherapy and pharmacology 1999;43(2):162-4.
1998: Mark M Zalupski; Anthony F Shields; Philip A Philip; M Kraut; Patricia M LoRusso; Lance K Heilbrun; Vainutis K Vaitkevicius
Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma.
Investigational new drugs 1998;16(1):93-6.
1997: Philip A Philip; Mark M Zalupski; Shirish M Gadgeel; Maha Hussain; Anthony F Shields
A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer.
Seminars in oncology 1997;24(6 Suppl 19):S19-86-S19-88.
1997: Mary Varterasian; Mark M Zalupski; Chatchada Karanes
The heterogeneity of leukemia occurring after treatment for sarcoma.
American journal of clinical oncology 1997;20(6):585-6.
1997: Anwar N Mohamed; Mark M Zalupski; James R Ryan; F Koppitch; Stanley P Balcerzak; R Kempf; Sandra R Wolman
Cytogenetic aberrations and DNA ploidy in soft tissue sarcoma. A Southwest Oncology Group Study.
Cancer genetics and cytogenetics 1997;99(1):45-53.
1997: H Kunikane; Mark M Zalupski; C Ramachandran; M A KuKuruga; David R Lucas; James R Ryan; AWTAR KRISHAN
Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas.
Cytometry 1997;30(4):197-203.
1997: Mark M Zalupski; Philip A Philip; Patricia M LoRusso; Anthony F Shields
Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma.
Cancer chemotherapy and pharmacology 1997;40(3):225-7.
1996: David R Lucas; James R Ryan; Mark M Zalupski; M L Gross; Yaddanapudi Ravindranath; B Ortman
Primary embryonal rhabdomyosarcoma of long bone. Case report and review of the literature.
The American journal of surgical pathology 1996;20(2):239-44.
1996: L G Hicks; S P Balcerzak; Mark M Zalupski
GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study.
Cancer investigation 1996;14(6):507-12.
1996: Brenda J Foster; Patricia M LoRusso; E Poplin; Mark M Zalupski; Manuel Valdivieso; Antoinette J Wozniak; Lawrence E Flaherty; D A Kasunic; R H Earhart; Laurence H Baker
Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.
Investigational new drugs 1996;13(4):321-6.
1996: Cynthia G Leichman; E Poplin; Mark M Zalupski; Y Garcia; A Grant; A Angeles; L DeJong; Lawrence Leichman
A pilot trial of continuous infusion 5-fluorouracil with levamisole for adjuvant therapy of colon cancer.
The Journal of infusional chemotherapy 1996;6(2):84-6.
1996: Laurence H Baker; Mark M Zalupski
Sarcomas: the role of adjuvant chemotherapy and a proposed new staging system.
Monographs in pathology 1996;38():240-51.
1995: Bruce G Redman; T H Chou; Mark M Zalupski; Joseph Primo Uberti; Lawrence E Flaherty; M Dan; L Sensenbrenner
Phase I trial of sequential cyclophosphamide, cyclosporin A, and interferon-alpha in patients with cancer: attempt to induce autologous graft-versus-host reaction to elicit an antitumor response.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(2):115-8.
1995: Mark M Zalupski; Laurence H Baker
Systemic adjuvant chemotherapy for soft tissue sarcomas.
Hematology/oncology clinics of North America 1995;9(4):787-800.
1995: O Altungoz; Aurelia Meloni-Ehrig; A Peier; Mark M Zalupski; Suzanne S Spanier; J S Brooks; Avery A Sandberg
Deletion 6q in three cases of mixed-type liposarcoma in addition to t(12;16)(q13;p11)
Cancer genetics and cytogenetics 1995;79(2):104-10.
1995: Mark M Zalupski; Laurence H Baker
Low-dose, continuous infusion 5-fluorouracil and oral etoposide for the treatment of advanced sarcomas.
The Journal of infusional chemotherapy 1995;5(3):129-31.
1994: S C Blair; Mark M Zalupski; Laurence H Baker
Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas.
American journal of clinical oncology 1994;17(6):480-4.
1994: Yavuz Ozisik; Aurelia Meloni-Ehrig; A Peier; O Altungoz; Suzanne S Spanier; Mark M Zalupski; S P Leong; Avery A Sandberg
Cytogenetic findings in 19 malignant bone tumors.
Cancer 1994;74(8):2268-75.
1994: F A Momin; Mark M Zalupski; Lance K Heilbrun; Lawrence E Flaherty; G Fyfe; Laurence H Baker; Bruce G Redman
Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(3):224-8.
1993: Mark M Zalupski; James R Ryan; John F Ensley; Z Maciorowski; H Pietraszkiewicz; M E Hussein; M Kukuruga; A S Sundareson; Laurence H Baker
Development and optimization of tissue preparative methodology for DNA content analysis of soft tissue neoplasms.
Cytometry 1993;14(8):922-30.
1993: Mark M Zalupski; J Benedetti; Stanley P Balcerzak; L F Hutchins; R J Belt; A Hantel; J Wendall Goodwin
Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.
Investigational new drugs 1993;11(4):337-41.
1993: Yavuz Ozisik; Aurelia Meloni-Ehrig; Mark M Zalupski; James R Ryan; F Qureshi; Avery A Sandberg
Deletion of chromosome 13 in osteosarcoma secondary to irradiation.
Cancer genetics and cytogenetics 1993;69(1):35-7.
1993: Mark M Zalupski; Z Maciorowski; James R Ryan; John F Ensley; M E Hussein; A S Sundareson; Laurence H Baker
DNA content parameters of paraffin-embedded soft tissue sarcomas: optimization of retrieval technique and comparison to fresh tissue.
Cytometry 1993;14(3):327-33.
1991: Mark M Zalupski; B Metch; Stanley P Balcerzak; W S Fletcher; Robert A Chapman; J D Bonnet; G R Weiss; J Ryan; R S Benjamin; Laurence H Baker
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.
Journal of the National Cancer Institute 1991;83(13):926-32.
1990: Mark M Zalupski; John F Ensley; J Ryan; S Selvaggi; Laurence H Baker; Sandra R Wolman
A common cytogenetic abnormality and DNA content alterations in dedifferentiated chondrosarcoma.
Cancer 1990;66(6):1176-82.
1990: Mark M Zalupski; James R Ryan; John F Ensley; Laurence H Baker
Cellular yields and DNA content parameters in osteogenic sarcomas.
La Chirurgia degli organi di movimento 1990;75(1 Suppl):15-7.
1988: Mark M Zalupski; Laurence H Baker
Ifosfamide.
Journal of the National Cancer Institute 1988;80(8):556-66.